Evidence map›Paper›PMID 36558902›Full record

ReviewPharmaceuticals (Basel, Switzerland)2022

The Glycosylation of Immune Checkpoints and Their Applications in Oncology.

Linlin Zheng, Qi Yang, Feifei Li, Min Zhu, Haochi Yang, Tian Tan, Binghuo Wu, Mingxin Liu, Chuan Xu, Jun Yin and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. CanPharmaceuticals (Basel, Switzerland) · 2024
    Review
  14. Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.International journal of biological sciences · 2024
    Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Linlin ZhengSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.
Qi YangBiotherapy Center, Third Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
Feifei LiCollaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Medical University, Nanning 530021, China.
Min ZhuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.
Haochi YangSchool of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Tian TanSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Binghuo WuDepartment of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Mingxin LiuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.
Chuan XuDepartment of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Jun YinSichuan Key Laboratory of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
Chenhui CaoSichuan Key Laboratory of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.ORCID 0000-0002-8119-0613
University of Electronic Science and Technology of China · CNChengdu University of Traditional Chinese Medicine · CNGuangxi Medical University · CNHarbin Medical University · CN

Funding

Foundation of Sichuan Educational Committee 18ZB0241National Natural Science Foundation of China 82203331National Postdoctoral Program for Innovative Talents BX20220052Natural Science Foundation of Sichuan Province 2022NSFSC1408Sichuan Science and Technology Program 2021YFS0227
6 · The paper itself

Abstract

Tumor therapies have entered the immunotherapy era. Immune checkpoint inhibitors have achieved tremendous success, with some patients achieving long-term tumor control. Tumors, on the other hand, can still accomplish immune evasion, which is aided by immune checkpoints. The majority of immune checkpoints are membrane glycoproteins, and abnormal tumor glycosylation may alter how the immune system perceives tumors, affecting the body's anti-tumor immunity. Furthermore, RNA can also be glycosylated, and GlycoRNA is important to the immune system. Glycosylation has emerged as a new hallmark of tumors, with glycosylation being considered a potential therapeutic approach. The glycosylation modification of immune checkpoints and the most recent advances in glycosylation-targeted immunotherapy are discussed in this review.

Indexed as

cancer therapyGlycoRNAglycosylationimmune checkpointspost-translational modifications

Identifiers

PMID36558902
PMCPMC9783268
OpenAlexW4309722369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.